6CM
LFCR icon

683 Capital Management’s Lifecore Biomedical LFCR Stock Holding History

683 Capital Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-31,456
Closed -$195K – 203
2023
Q4 		$195K Buy
+31,456
New +$218K 0.02% 204

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VWA
Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

683 Capital Management's LFCR Position: Q1 2024 in Review

683 Capital Management sold out of Lifecore Biomedical (LFCR) in Q1 2024, closing a stake of 31,456 shares — an estimated $195K sold.

683 Capital Management first reported a position in LFCR in Q4 2023 and held it in 1 quarter. The position peaked at $195K in Q4 2023. 79 funds tracked by Wall St. Rank hold LFCR as of Q1 2024.

  • 683 Capital Management reported no remaining Lifecore Biomedical position as of Q1 2024 after selling out during the quarter.
  • 683 Capital Management sold 31,456 Lifecore Biomedical shares in Q1 2024, an estimated $195K.
  • 683 Capital Management first reported a position in Lifecore Biomedical in Q4 2023 and held it in 1 quarter.
  • 683 Capital Management's Lifecore Biomedical position peaked at $195K in Q4 2023.
  • 79 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2024.

Based on 683 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.